Pernix Therapeutics to Report First Quarter 2014 Financial Results on May 12, 2014

Management to Host a Conference Call on May 12, 2014 at 9:00 a.m. EDT

Business Wire

MORRISTOWN, N.J.--(BUSINESS WIRE)--

Pernix Therapeutics Holdings, Inc. (PTX), a specialty pharmaceutical company, today announced that it will release its first quarter 2014 financial results before the U.S. stock market opens on Monday, May 12, 2014 and has scheduled a conference call at 9:00 a.m. EDT that day to discuss the financial results.

The conference call will feature remarks by Doug Drysdale, Chairman of the Board, President, and Chief Executive Officer, and Tracy Clifford, Principal Accounting Officer. To participate in the conference call, please dial (877) 312-8783 (domestic) or (408) 940-3874 (international). Participants can reference the passcode 25970459. Please dial in approximately 5 minutes prior to the call.

The conference call will also be available via a live listen-only webcast and can be accessed through the Investor Relations section of the Company’s website www.pernixtx.com. The passcode is 25970459. Please allow extra time prior to the call to visit the Company’s website and download any software that may be needed to listen to the webcast.

A replay of the conference call will be available through May 19, 2014, at (855) 859-2056 domestic and (404) 537-3406 international. The passcode for the replay is 25970459. An online archive of the webcast will be available on the Company’s website for 30 days following the call.

About Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded pharmaceutical products. The Company markets a portfolio of branded products, including: CEDAX®, an antibiotic for middle ear infections and a number of treatments for cough and cold conditions including ZUTRIPRO®, REZIRA® and VITUZ®. The Company also markets SILENOR, a non-narcotic product for the treatment of insomnia and KHEDEZLA, a treatment for major depressive disorder. The Company promotes its branded products to physicians through its Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. Founded in 1996, the Company is now based in Morristown, New Jersey.

Additional information about Pernix is available on the Company’s website located at www.pernixtx.com.

Contact:
Pernix Therapeutics Holdings, Inc.
Doug Drysdale, (843) 654-7720 Ext. 7407
President and CEO
ddrysdale@pernixtx.com

View Comments (0)